Table 3. Univariate analyses of prognostic factors for survival.
| 3-year PFS | 3-year OS | |||
|---|---|---|---|---|
| N=45 | N=44 | |||
| Percent (95% CI) | P-value | Percent (95% CI) | P-value | |
| Sex | 0.580 | 0.336 | ||
| Male | 58.2 (41.9–74.5) | 58.9 (40.9–76.9) | ||
| Female | 62.5 (29.0–96.0) | 72.9 (40.6–100.0) | ||
| Age (years) | 0.572 | 0.687 | ||
| ⩽60 | 55.9 (37.9–73.9) | 60.3 (41.9–78.7) | ||
| >60 | 65.0 (40.1–89.9) | 59.6 (22.4–96.8) | ||
| Smoking | 0.702 | 0.481 | ||
| Yes | 58.7 (42.0–75.4) | 60.2 (42.0–78.4) | ||
| No | 60.0 (29.6–90.4) | 66.7 (35.1–98.3) | ||
| Stage | 0.002 | 0.003 | ||
| III | 75.0 (45.0–100.0) | 83.3 (53.5–100.0) | ||
| IVA | 68.9 (51.8–86.0) | 70.7 (53.5–87.9) | ||
| IVB | 0 | 0 | ||
| Tumour location | <0.001 | <0.001 | ||
| Oral cavity | 0 | 0 | ||
| Others | 66.2 (51.1–81.3) | 70.7 (54.8–86.6) | ||
| Performance status | 0.491 | 0.986 | ||
| 0 | 50.0 (21.8–78.2) | 66.7 (40.0–93.4) | ||
| 1 | 62.0 (44.9–79.1) | 60.3 (41.5–79.1) | ||
| ERCC1 expression | 0.036 | 0.013 | ||
| High | 49.4 (31.8–67.0) | 45.5 (23.9–67.1) | ||
| Low | 83.3 (62.1–100.0) | 91.7 (76.0–100.0) | ||
| Chemotherapy regimen | 0.245 | 0.151 | ||
| Cisplatin | 46.0 (19.9–72.1) | 49.7 (22.8–76.6) | ||
| Fluorouracil+cisplatin | 50.0 (10.0–90.0) | 50.0 (10.0–90.0) | ||
| Taxane+cisplatin | 68.2 (48.8–87.6) | 73.9 (53.5–94.3) | ||
| Completion of chemotherapy | 0.192 | 0.078 | ||
| Yes | 61.6 (45.7–77.5) | 65.6 (48.5–82.7) | ||
| No | 42.9 (6.2–79.6) | 42.9 (6.2–79.6) | ||
| Radiation dose (Gy) | 0.296 | 0.381 | ||
| ⩽66.6 | 48.5 (27.9–69.1) | 55.3 (34.3–76.3) | ||
| >66.6 | 70.0 (50.0–90.0) | 67.4 (42.3–92.5) |
ERCC1=excision repair cross-complementation group 1; OS=overall survival; PFS=progression-free survival.